PMID- 7964954
OWN - NLM
STAT- MEDLINE
DCOM- 19941202
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 12
IP  - 11
DP  - 1994 Nov
TI  - Allogeneic versus autologous purged bone marrow transplantation for 
      neuroblastoma: a report from the Childrens Cancer Group.
PG  - 2382-9
AB  - PURPOSE: We have compared the toxicity, relapse rate, and progression-free 
      survival (PFS) of high-risk neuroblastoma patients receiving identical induction 
      therapy and myeloablative chemotherapy plus total-body irradiation (TBI) followed 
      by allogeneic or autologous purged bone marrow transplantation (BMT). PATIENTS 
      AND METHODS: Fifty-six patients with high-risk neuroblastoma underwent BMT at 
      investigator and parent option if they did not have progressive disease after 
      induction chemotherapy with cisplatin, cyclophosphamide, doxorubicin, and 
      etoposide. After surgery and local radiation to residual tumor, myeloablative 
      therapy consisting of etoposide, melphalan, cisplatin, and TBI was given followed 
      by BMT. Patients with human leukocyte antigen (HLA)-compatible siblings received 
      allogeneic bone marrow (n = 20). The remaining patients (n = 36) received 
      autologous bone marrow that had undergone multimodality purging and had no 
      remaining detectable tumor cells by immunocytology. RESULTS: Four of 20 
      allogeneic patients had a treatment-related death, compared with three of 36 
      autologous patients (P = .21). The relapse rate among allogeneic BMT patients was 
      69%, compared with 46% for autologous BMT patients (P = .14). The estimated PFS 
      rates 4 years after BMT were 25% for allogeneic BMT patients and 49% for 
      autologous BMT patients (P = .051). CONCLUSION: Overall outcome for patients with 
      neuroblastoma given this same induction therapy followed by autologous purged 
      marrow was similar to that with allogeneic marrow, although bias in patients 
      selection cannot be excluded in a nonrandomized comparison.
FAU - Matthay, K K
AU  - Matthay KK
AD  - Department of Pediatrics, University of California School of Medicine, San 
      Francisco.
FAU - Seeger, R C
AU  - Seeger RC
FAU - Reynolds, C P
AU  - Reynolds CP
FAU - Stram, D O
AU  - Stram DO
FAU - O'Leary, M C
AU  - O'Leary MC
FAU - Harris, R E
AU  - Harris RE
FAU - Selch, M
AU  - Selch M
FAU - Atkinson, J B
AU  - Atkinson JB
FAU - Haase, G M
AU  - Haase GM
FAU - Ramsay, N K
AU  - Ramsay NK
LA  - eng
GR  - CA02649/CA/NCI NIH HHS/United States
GR  - CA13539/CA/NCI NIH HHS/United States
GR  - CA53329/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Bone Marrow Transplantation/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Drug Administration Schedule
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - Neoplasm Recurrence, Local
MH  - Neuroblastoma/drug therapy/pathology/*therapy
MH  - Pilot Projects
MH  - Prognosis
MH  - Transplantation, Autologous
MH  - Transplantation, Homologous
MH  - Whole-Body Irradiation
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
AID - 10.1200/JCO.1994.12.11.2382 [doi]
PST - ppublish
SO  - J Clin Oncol. 1994 Nov;12(11):2382-9. doi: 10.1200/JCO.1994.12.11.2382.